- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01404182
Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons
Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine (Trivalent, Seasonal, Active Ingredient Content: 15 μg HA/Strain/0.5 mL) in Adults and Elderly Persons
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Immunogenicity Objective:
To assess immunogenicity of a single intramuscular (IM) injection of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each), as measured by haemagglutination inhibition (HI) test.
Safety and Tolerability Objectives:
To evaluate safety and tolerability (incidence of adverse events) of a single intramuscular (IM) injection of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Veszprem, Hungary, H-8200
- Fourmed Gyogyhaz Kft.
-
-
Pest
-
Pilisvorosvar, Pest, Hungary, H-2097
- Family Doctor's Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18 to 60 years, elderly persons aged over 60 years, both sexes, mentally competent
- Are in good health (as determined by vital signs and existing medical condition) or are in stable medical condition. Subjects will not be excluded with known adequately treated clinically significant organ or systemic diseases (e.g. asthma or diabetes), such that, in the opinion of the investigator, the significance of the disease will not compromise the subject's participation in the study
- Female volunteers aged 18-60 years (i.e. participants of childbearing potential) with a negative result from the urine pregnancy test prior to vaccination who agrees to use an acceptable contraception method or abstinence throughout the trial and not become pregnant for the duration of the study.
- Capability of participants to understand and comply with planned study procedures
- Participants aged above 18 years provide written informed consent prior to initiation of study procedures
- Absence of existence of any exclusion criteria.
Exclusion Criteria:
- Pregnancy, breast feeding or positive urine pregnancy test at baseline prior to vaccination. Female subjects who are able to bear children but not willing to use an acceptable contraception method for the duration of the study.
- Known hypersensitivity to eggs, chicken protein, thiomersal, formaldehyde, gentamycin, ciprofloxacin, neomycin or any other component of the vaccine
- History of Guillain-Barré syndrome
- History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine
- Serious disease, such as cancer, autoimmune disease, advanced arteriosclerotic disease, complicated diabetes mellitus, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure
- Immunosuppressive therapy within the past 36 months
- Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids
- Receipt of immunostimulants,
- Receipt of parenteral immunoglobulin, blood products and/or plasma derivate within the past 3 months
- Suspected or HIV, HBV or HCV infection
- Acute disease and/or axillary temperature ≥37oC within the past 3 days
- Vaccine therapy within the past 4 weeks
- Influenza vaccination (any kind) within the past 6 months
- Experimental drug therapy within the past 4 weeks
- Concomitant participation in another clinical study
- Any condition which, in the opinion of the investigator, may interfere with the evaluation of the study
- Past or current psychiatric disease of the volunteer that upon judgement of the investigator may have effect on the objective decision-making of the volunteer
- Alcohol or drug abuse of the participant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Influenza vaccination
Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
|
Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Post vaccination HI antibody titer
Time Frame: 21-28 days following vaccination
|
21-28 days following vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse reactions
Time Frame: 21-28 days following vaccination
|
21-28 days following vaccination
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ferenc Tamás, MD, Family Doctor's Office Pilisvorosvar
- Principal Investigator: László Sinka, MD, Fourmed Gyogyhaz Kft.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FluvalAB-H-YL2011
- 2011-002158-30 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on Vaccination with Fluval AB influenza vaccine
-
Fluart Innovative Vaccine Ltd, HungaryCompletedInfluenza, Human | Novel 2009 Influenza H1N1Hungary
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Fluart Innovative Vaccine Ltd, HungaryCompletedInfluenza ProphylaxisHungary
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
St. Antonius HospitalCompletedNon-Hodgkin Lymphoma (NHL)Netherlands
-
Korea University Guro HospitalCompletedPneumococcal Infections | Influenza, HumanKorea, Republic of
-
Sinovac Biotech Co., LtdCompletedInfluenza and PneumoniaChina
-
Fluart Innovative Vaccine Ltd, HungaryCompleted